Meeting
2015 ASCO Annual Meeting
Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.
Authors
Sung Hee Lim
Samsung Medical Center, Seoul, Korea South
Sung Hee Lim , Tae Won Kim , Sae-Won Han , Hye Jin Kang , In Gyu Hwang , Ji Yun Lee , Min-Young Lee , Hae Su Kim , Seung Tae Kim , Jeeyun Lee , Joon Oh Park , Se Hoon Park , Young Suk Park , Ho Yeong Lim , Jun Soo Ham , Seonggyu Byeon , Hee Kyung Kim , Won Ki Kang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01238094
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3576)
DOI
10.1200/jco.2015.33.15_suppl.3576
Abstract #
3576
Poster Bd #
68
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Differential association of proton pump inhibitors with efficacy of capecitabine and 5-fluorouracil in metastatic colorectal cancer: A post-hoc analysis from AXEPT phase III trial.
First Author: Sun Young Kim
Poster
2017 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).
First Author: Masato Nakamura
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang
Poster
2020 Gastrointestinal Cancers Symposium
Efficacy and safety of the combination of aflibercept with fluorouracil, leucovorin, and irinotecan in patients aged 70 years and older with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen in Spain: A retrospective multicenter cohort study.
First Author: Laura Gutiérrez Sainz